Secondary data use of tocilizumab clinical studies to address regulatory needs for rare and pediatric trials
As part of the European INVENTS research project (Innovative designs, extrapolation, simulation methods and evidence-tools for rare and pediatric diseases), a study involving the use of secondary data from 10,000 patients in 20 clinical studies has been registered in the ISRCTN registry.
